CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 42 enrolled
Drug / intervention
LY900014 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03286751
NCT03286751Phase 1Completed
CompareCT.gov

A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 and Humalog Across Different Subcutaneous Doses in Healthy Subjects

Eli Lilly and Company·interventional·Posted Sep 18, 2017·Updated May 1, 2020

In Brief

A Phase 1 clinical trial evaluating LY900014 and Insulin Lispro for Diabetes Mellitus, Type 2. Completed, enrolled 42 participants across 2 sites.

Detailed Summary

This study compares LY900014, a drug that lowers blood sugar, with insulin lispro (Humalog). Both drugs are given by injection under the skin of the abdomen. The study will be conducted in healthy people to investigate how quickly and how much LY900014 is absorbed and the effect of different doses of LY900014 on blood sugar levels in comparison with insulin lispro. The study will last about 7 to 12 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedSep 18, 2017
Enrollment StartOct 13, 2017
Primary CompletionFeb 6, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.8 years ago

Interventions

LY900014drug

Administered SC

Insulin Lisprodrug

Administered SC